New App Helps Vets And Nurses Further Improve Cancer Screening Device
3 months ago 
345 views
HT Vista, who uses an AI-based algorithm to screen dermal and subcutaneous masses in dogs, has developed a user-friendly data collection app, HT app, which has contributed to improving the sensitivity of the HT Vista device from 85% to 90% and increasing the negative predictive value from 97% to 98%. The app records scans performed by vets with the opportunity to upload cytology and histopathology results which are then analysed to monitor performance. The app, which was developed following demand from clinics, is helping to create a sense of community among practices who use the HT Vista device and drive confidence in results.
Liron Levy-Hirsch, Managing Director of HT Vista, says, “The HT app has provided us with over 700 additional validated scans to analyse this year alone. The validation process is well controlled, whereby we use the lab results to tag the scans as benign or malignant and let the algorithm know if it was correct or not. The more we train the algorithm the more accurate it becomes, and it is extremely exciting to see the sensitivity increase to 90% and the NPV to 98%.”
The creation of the app came from a dedicated customer success programme, “We listened to what the vets using the device need” continues Liron “By having a portal to upload lab results alongside the device’s results not only do we further improve the device, but we also increase confidence among our vets and nurses that the device is a reliable tool. We are very grateful to everyone who had been uploading information and we work closely with all our practices to ensure they have all the support they need to do so.”
The HT Vista device underwent rigorous validation before being launched last year and the team at HT Vista continues to develop the device with data from scans and accompanying cytology or histopathology results. As well as data received via the HT app, information is gathered from the internal team who work in collaboration with GP validation clinics and oncology centres worldwide*.
As HT Vista’s expansion into practices grows across Europe following partnership with VetFamily and a successful roll out of online demos both in Europe and in the US, the company is looking forward to the future, “We are constantly progressing and innovating. Our goals for 2024 are to continue gathering more cases to further improve the specificity and positive predictive value. We remain committed to supporting veterinary professionals maximise the potential the HT Vista device has within practices, with our dedicated training and customer success services.” continues Liron.
For more information on the HT Vista device veterinary professionals are welcomed to book an online demo with an HT Vista demo, to allow opportunity for any questions along with an introduction to the device and its benefits. No-obligation demos can be booked online at https://ht-vista.uk/vistademo/
More from HT Vista
- HT Vista return to BSAVA to celebrate a successful first year with big giveaway
- HT Vista expands into Europe and the USA via new VetFamily partnership
- Newly published paper validates innovative AI-powered screening device for canine dermal and subcutaneous masses
- HT Vista celebrates a successful first month and prepares to showcase at BVA Live
